Free Trial

Femasys Q1 2024 Earnings Report

Femasys logo
$1.19 -0.04 (-3.25%)
As of 04/4/2025 04:00 PM Eastern

Femasys EPS Results

Actual EPS
-$0.17
Consensus EPS
-$0.22
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

Femasys Revenue Results

Actual Revenue
$0.27 million
Expected Revenue
$0.30 million
Beat/Miss
Missed by -$30.00 thousand
YoY Revenue Growth
N/A

Femasys Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Remove Ads

Femasys Earnings Headlines

Femasys (NASDAQ:FEMY) Receives "Buy" Rating from HC Wainwright
Femasys reports FY24 EPS (85c), consensus (81c)
Your Retirement Is Caught in the Crossfire
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.
Femasys enters partnership with CNY Fertility
See More Femasys Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Femasys? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Femasys and other key companies, straight to your email.

About Femasys

Femasys (NASDAQ:FEMY), a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

View Femasys Profile

More Earnings Resources from MarketBeat